Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
3期
进行中（已停止招募）
NCT01874353
| 适应症 | Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy |
|---|
| 分期 | 3期 |
|---|
| 申办方 | AstraZeneca |
|---|
| 状态 | 进行中（已停止招募） |
|---|
| 受试者人数 | 327 人 |
|---|
| 干预（药物） | Olaparib 300mg tablets, Placebo to match olaparib 300mg |
|---|
| 开始日期 | 2013年9月3日 |
|---|
| 完成日期 | 2016年9月19日 |
|---|
| 结果公布日 | 2018年2月7日 |
|---|
摘要
A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary peritoneal and / or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum based chemotherapy.
Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1)
Radiologic scans performed at baseline then every ~12 weeks up to 72 weeks, then every ~ 24 weeks thereafter until objective radiological disease progression. Assessed until 19 Sep 2016 DCO (16 Jan 2017 DCO for China Cohort); up to a maximum of 36 months. · Months
| Olaparib 300mg Tablets (Global Cohort) | 19.1 Months |
|---|
| Placebo Tablets (Global Cohort) | 5.5 Months |
|---|
| Olaparib 300mg Tablets (China Cohort) | 13.8 Months |
|---|
| Placebo Tablets (China Cohort) | 5.5 Months |
|---|
| p-value | <0.0001 |
|---|
| Hazard Ratio (HR) | 0.30 (95% CI 0.22–0.41) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。